Pharmacokinetics and safety of the combination of KL130008 and methotrexate in rheumatoid arthritis patients: a multicenter, open-label phase Ib trial
This trial was registered with the Chinese Clinical Trial Register (ChiCTR2100050764) on 4 September 2021.
Authors
- Junyou Ge (ORCID: https://orcid.org/0000-0002-6524-0078)
- Ping Feng (ORCID: https://orcid.org/0000-0001-5488-0814)
- Jieping Zeng (ORCID: https://orcid.org/0009-0007-5569-9954)
- Man Chen (ORCID: https://orcid.org/0000-0001-7030-9968)
- Huiping Gong (ORCID: https://orcid.org/0000-0002-8221-9318)
- Yue Cheng (ORCID: https://orcid.org/0000-0003-4697-4081)
- Linzhong Cheng
- Bingjie Wu (ORCID: https://orcid.org/0009-0001-4843-0777)
- Ziyi Xu (ORCID: https://orcid.org/0000-0002-5747-5707)
- Yezhe Cheng
- Yi Liu (ORCID: https://orcid.org/0000-0001-9748-0650)
- Wenping Wang (ORCID: https://orcid.org/0000-0002-0775-5890)
- Yuan Li (ORCID: https://orcid.org/0000-0003-1694-5108)
- Jing Yu (ORCID: https://orcid.org/0000-0002-3208-0821)
- Shuangqing Du (ORCID: https://orcid.org/0000-0002-6417-2341)
- Honghu Tang (ORCID: https://orcid.org/0000-0002-5029-2828)
- Xiaoping Jin
Institutions
- Target (United States) (US)
- Changzhi Medical College (CN)
- National Medical Products Administration (CN)
- Sichuan University (CN)
- Liaoning University of Traditional Chinese Medicine (CN)
- West China Hospital of Sichuan University (CN)
- BioEnergetics (United States) (US)
- People's Hospital of Cangzhou (CN)
- Kelun Group (China) (CN)
- Affiliated Hospital of Liaoning University of Traditional Chinese Medicine (CN)
- Chengdu University of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- Expert Opinion on Drug Metabolism & Toxicology
- Published
- 2025-09-26
- DOI
- https://doi.org/10.1080/17425255.2025.2568188
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00